ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The investment firm Ampersand Capital has acquired Louisville, Kentucky–based Peptides International and merged it with New England Peptide, one of its portfolio companies. Peptides International will add catalog and custom synthesis services to New England Peptide’s custom design and manufacturing services for pharmaceutical peptide and antibody products. “This transaction adds meaningful scale, capabilities, customer relationships, and a similarly strong market reputation to what we have built,” says Sam Massoni, CEO of New England Peptide.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter